Noradrenergic regulation of glial activation: Molecular mechanisms and therapeutic implications

Current Neuropharmacology

Volumn 12, Issue 4, 2014, Pages 342-352

  Braun, David ^a   Madrigal, Jose L M ^b   Feinstein, Douglas L ^a,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Alzheimer s disease; Amyloid; EAE; GFAP; Locus coeruleus; Multiple sclerosis; Noradrenaline; Review; Transgenic mice; Tyrosine hydroxylase

Indexed keywords

ATOMOXETINE; THREO 3, 4 DIHYDROXYPHENYLSERINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; DISEASE COURSE; DOWN SYNDROME; GLIA CELL; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; NORADRENERGIC SYSTEM; PARKINSON DISEASE; POSTTRAUMATIC STRESS DISORDER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84911480443     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X12666140828220938     Document Type: Article

References (124)

1. Szabadi, E. Functional neuroanatomy of the central noradrenergic system. J. Psychopharmacol., 2013, 27, 659-693. doi: 10. 1177/0269881113490326.
2. Hertz, L.; Lovatt, D.; Goldman, S. A.; Nedergaard, M. Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca(2+)]i. Neurochem. Int., 2010, 57, 411-420. DOI: 10. 1016/j. neuint. 2010. 03. 019.
3. O'Donnell, J.; Zeppenfeld, D.; McConnell, E.; Pena, S.; Nedergaard, M. Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem. Res., 2012, 37, 2496-2512. DOI10. 1007/s11064-012-0818-x.
4. Vardjan, N.; Kreft, M.; Zorec, R. Dynamics of beta-adrenergic/cAMP signaling and morphological changes in cultured astrocytes. Glia, 2014, 62, 566-579. DOI: 10. 1002/glia. 22626.
5. Du T.; Li B.; Liu S.; Zang P.; Prevot V.; Hertz L.; Peng L. ERK phosphorylation in intact, adult brain by alpha(2)-adrenergic transactivation of EGF receptors. Neurochem. Int., 2009, 55, 593-600. DOI: 10. 1016/j. neuint. 2009. 05. 016.
6. Huang, R. and Hertz, L. Clonidine enhances astrocytic glutamine uptake by authentic alpha 2-adrenoceptor stimulation. Neuroreport, 1994, 5, 632-634. DOI: 10. 1097/00001756-199401000-00025.
7. Zhao, Z.; Code, W. E.; Hertz, L. Dexmedetomidine, a potent and highly specific alpha 2 agonist, evokes cytosolic calcium surge in astrocytes but not in neurons. Neuropharmacology, 1992, 31, 1077-1079. DOI: 10. 1016/0028-3908(92)90111-2.
8. Magistretti, P. J.; Sorg, O.; Yu, N.; Martin, J. L.; Pellerin, L. Neurotransmitters regulate energy metabolism in astrocytes: implications for the metabolic trafficking between neural cells. Dev. Neurosci., 1993, 15, 306-312. DOI: 10.1159/000111349.
9. Subbarao, K. V. and Hertz, L. Effect of adrenergic agonists on glycogenolysis in primary cultures of astrocytes. Brain Res., 1990, 536, 220-226. DOI: 10. 1016/0006-8993(90)90028-A.
10. Pesce, L.; Guerrero, C.; Comellas, A.; Ridge, K. M.; Sznajder, J. I. beta-agonists regulate Na, K-ATPase via novel MAPK/ERK and rapamycin-sensitive pathways. FEBS Lett., 2000, 486, 310-314. DOI: 10. 1016/S0014-5793(00)02298-5.
11. Minghetti, L.; Nicolini, A.; Polazzi, E.; Creminon C.; Maclouf J.; Levi, G. Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia, 1997, 19, 152-160. DOI: 10. 1002/(SICI)1098-1136(199702)19: 2<152:: AID-GLIA>63. 0. CO; 2-2.
12. Galea, E. and Feinstein, D. L. Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP. FASEB J., 1999, 13, 2125-2137. PMID: 10593859.
13. Szabo, C.; Hasko, G.; Zingarelli, B.; Nemeth, Z. H.; Salzman, A. L.; Kvetan, V.; Pastores, S. M.; Vizi, E. S. Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide produciton and protects against the development of vascular hyporeactivity in endotoxaemia. Immunology, 1997, 90, 95-100. DOI: 10. 1046/j. 1365-2567. 1997. 00137. x.
14. Frohman, E. M.; Vayuvegula, B.; Gupta, S.; van den, N. S. Norepinephrine inhibits gamma-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via beta-2-adrenergic signal transduction mechanisms. Proc. Natl. Acad. Sci. U. S. A, 1988, 85, 1292-1296. PubMed ID2829222.
15. Feinstein, D. L.; Galea, E.; Reis, D. J. Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures. J. Neurochem., 1993, 60, 1945-1948. DOI: 10. 1111/j. 1471-4159. 1993. tb13425. x.
16. Dello, R. C.; Boullerne, A. I.; Gavrilyuk, V.; Feinstein, D. L. Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J. Neuroinflammation, 2004, 1, 9. DOI: 10. 1186/1742-2094-1-9.
17. De Keyser, J.; Laureys, G.; Demol, F.; Wilczak, N.; Mostert, J.; Clinckers, R. Astrocytes as potential targets to suppress inflammatory demyelinating lesions in multiple sclerosis. Neurochem. Int., 2010, 57, 446-450. DOI: 10. 1016/j. neuint. 2010. 02. 012.
18. Laureys, G.; Clinckers, R.; Gerlo, S.; Spooren, A.; Wilczak, N.; Kooijman, R.; Smolders, I.; Michotte, Y.; De Keyser, J. Astrocytic beta(2)-adrenergic receptors: from physiology to pathology. Prog. Neurobiol., 2010, 91, 189-199. DOI: 10. 1016/j. pneurobio. 2010. 01. 011.
19. Gavrilyuk, V.; Horvath, P.; Weinberg, G.; Feinstein, D. L. A 27-bp region of the inducible nitric oxide synthase promoter regulates expression in glial cells. J. Neurochem., 2001, 78, 129-140. DOI: 10. 1046/j. 1471-4159. 2001. 00375. x.
20. Madrigal, J. L.; Feinstein, D. L.; Dello, R. C. Norepinephrine protects cortical neurons against microglial-induced cell death. J. Neurosci. Res., 2005, 81, 390-396. DOI: 10. 1002/jnr. 20481.
21. Martel, J.; Chopin, P.; Colpaert, F.; Marien, M. Neuroprotective effects of the alpha2-adrenoceptor antagonists, (+)-efaroxan and (+/-)-idazoxan, against quinolinic acid-induced lesions of the rat striatum. Exp. Neurol., 1998, 154, 595-601. DOI: 10. 1006/exnr. 1998. 6942.
22. Gustafson, I.; Westerberg, E.; Wieloch, T. Protection against ischemia-induced neuronal damage by the alpha 2-adrenoceptor antagonist idazoxan: influence of time of administration and possible mechanisms of action. J Cereb. Blood Flow Metab, 1990, 10, 885-894. doi: 10. 1038/jcbfm. 1990. 145.
23. Veyrac A.; Didier A.; Colpaert F.; Jourdan F.; Marien M. Activation of noradrenergic transmission by alpha2-adrenoceptor antagonists counteracts deafferentation-induced neuronal death and cell proliferation in the adult mouse olfactory bulb. Exp. Neurol., 2005, 194, 444-456. DOI: 10. 1016/j. expneurol. 2005. 03. 004.
24. Kalinin, S.; Polak, P. E.; Madrigal, J. L.; Gavrilyuk, V.; Sharp, A.; Chauhan, N.; Marien M.; Colpaert, F.; Feinstein, D. L. Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist. Antioxid. Redox. Signal., 2006, 8, 873-883. doi: 10. 1089/ars. 2006. 8. 873.
25. Scullion, G. A.; Kendall, D. A.; Marsden, C. A.; Sunter, D.; Pardon, M. C. Chronic treatment with the alpha2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APPxPS1 transgenic mice without altering beta-amyloid plaque load or astrocytosis. Neuropharmacology, 2011, 60, 223-234. DOI: 10. 1016/j. neuropharm. 2010. 09. 002.
26. O'Sullivan, J. B.; Ryan, K. M.; Harkin, A.; Connor, T. J. Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. J. Neuroimmunol., 2010, 220, 34-42. DOI: 10. 1016/j. jneuroim. 2009. 12. 007.
27. McNamee, E. N.; Griffin, E. W.; Ryan, K. M.; Ryan, K. J.; Heffernan S.; Harkin, A.; Connor, T. J. Noradrenaline acting at beta-adrenoceptors induces expression of IL-1beta and its negative regulators IL-1 ra and IL-1RII, and drives an overall antiinflammatory phenotype in rat cortex. Neuropharmacology, 2010, 59, 37-48. DOI: 10. 1016/j. neuropharm. 2010. 03. 014.
28. Hashioka, S.; Klegeris, A.; Monji A.; Kato, T.; Sawada, M.; McGeer P. L.; Kanba S. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp. Neurol., 2007, 206, 33-42. DOI: 10. 1016/j. expneurol. 2007. 03. 022.
29. Russo-Neustadt, A.; Beard, R. C.; Cotman, C. W. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology, 1999, 21, 679-682. doi: 10. 1016/S0893-133X(99)00059-7.
30. Malberg, J. E.; Eisch, A. J.; Nestler, E. J.; Duman, R. S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci., 2000, 20, 9104-9110. PMID: 11124987.
31. Prince, J. B. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc. Psychiatr. Clin. N. Am., 2006, 15, 13-50. DOI: 10. 1016/j. chc. 2005. 08. 002.
32. Simonini, M. V.; Polak P. E.; Sharp, A.; McGuire, S.; Galea, E.; Feinstein D. L. Increasing CNS noradrenaline reduces EAE severity. J. Neuroimmune Pharmacol., 2010, 5, 252-259. DOI10. 1007/s11481-009-9182-2.
33. Mohs, R. C.; Shiovitz, T. M.; Tariot, P. N.; Porsteinsson, A. P.; Baker, K. D.; Feldman, P. D. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. Am. J. Geriatr. Psychiatry, 2009, 17, 752-759. doi: 10. 1097/JGP. 0b013e3181aad585.
34. Goldstein, D. S. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc. Drug Rev., 2006, 24, 189-203. DOI: 10. 1111/j. 1527-3466. 2006. 00189. x.
35. Nakamura, K.; Ahmed, M.; Barr, E.; Leiden, J. M.; Kang, U. J. The localization and functional contribution of striatal aromatic L-amino acid decarboxylase to L-3, 4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models. Cell Transplant., 1999, 9, 567-576. PMID: 11144954.
36. Rommelfanger, K. S.; Edwards, G. L.; Freeman, K. G.; Liles, L. C.; Miller, G. W.; Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc. Natl. Acad. Sci. U. S. A, 2007, 104, 13804-13809. doi: 10. 1073/pnas. 0702753104.
37. Kalinin, S.; Polak, P. E.; Lin, S. X.; Sakharkar, A. J.; Pandey, S. C.; Feinstein, D. L. The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol. Aging, 2012, 33, 1651-1663. DOI: 10. 1016/j. neurobiolaging. 2011. 04. 012.
38. Eisenhofer, G. and Finberg, J. P. Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats. J. Pharmacol. Exp. Ther., 1994, 268, 1242-1251. PMID: 8138937.
39. Huang, G.; Dragan, M.; Freeman, D.; Wilson, J. X. Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons. Glia, 2005, 51, 47-55. DOI: 10. 1002/glia. 20185.
40. Helkamaa, T.; Reenila, I.; Tuominen, R. K.; Soinila, S.; Vaananen, A.; Tilgmann, C.; Rauhala, P. Increased catechol-O-methyltrans-ferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion. Neurochem. Int., 2007, 51, 412-423. DOI: 10. 1016/j. neuint. 2007. 04. 020.
41. Myohanen, T. T.; Schendzielorz, N.; Mannisto, P. T. Distribution of catechol-O-methyltransferase (COMT) proteins and enzymatic activities in wild-type and soluble COMT deficient mice. J. Neurochem., 2010, 113, 1632-1643. DOI: 10. 1111/j. 1471-4159. 2010. 06723. x.
42. Muller, T. Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference. Patient. Prefer. Adherence., 2009, 3, 51-59. DOI http://dx. doi. org/10. 2147/ PPA. S4084.
43. Muller, T.; Kuhn, W.; Przuntek, H. Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? J. Neural Transm. Gen. Sect., 1992, 92, 187-195. DOI10. 1007/BF01244877.
44. McNamee, E. N.; Ryan, K. M.; Kilroy, D.; Connor, T. J. Noradrenaline induces IL-1ra and IL-1 type II receptor expression in primary glial cells and protects against IL-1beta-induced neurotoxicity. Eur. J. Pharmacol., 2010, 626, 219-228. DOI: 10. 1016/j. ejphar. 2009. 09. 054.
45. Madrigal, J. L.; Leza, J. C.; Polak, P.; Kalinin, S.; Fein stein, D. L. Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J. Neurosci., 2009, 29, 263-267. doi: 10. 1523/JNEUROSCI. 4926-08. 2009.
46. Mangano, E. N.; Peters, S.; Litteljohn, D.; So, R.; Bethune, C.; Bobyn J.; Clarke M.; Hayley S. Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson's disease. Neurobiol. Dis., 2011, 43, 99-112. DOI: 10. 1016/j. nbd. 2011. 02. 011.
47. Boyd T. D.; Bennett, S. P.; Mori, T.; Governatori, N.; Runfeldt, M.; Norden, M.; Padmanabhan, J.; Neame, P.; Wefes, I.; Sanchez-Ramos, J.; Arendash, G. W.; Potter, H. GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. J. Alzheimers. Dis., 2010, 21, 507-518. DOI: 10. 1016/jjalz. 2010. 05. 1962.
48. Kosloski, L. M.; Kosmacek, E. A.; Olson, K. E.; Mosley, R. L.; Gendelman, H. E. GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxicated mice. J. Neuroimmunol., 2013, 265, 1-10. DOI: 10. 1016/j jneuroim. 2013. 10. 009.
49. Buc, M. [Immunogenetic mechanisms in autoimmune processes: disorders of immune regulatory mechanisms, genetic determination of autoimmunity, effector mechanisms of autoimmune processes and their therapy]. Bratisl. Lek. Listy, 1996, 97, 660-668. PMID: 9117429.
50. Lowther, D. E. and Hafler, D. A. Regulatory T cells in the central nervous system. Immunol. Rev., 2012, 248, 156-169. DOI: 10. 1111/j. 1600-065X. 2012. 01130. x.
51. Yadav, A.; Saini, V.; Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin. Chim. Acta, 2010, 411, 1570-1579. DOI: 10. 1016/j. cca. 2010. 07. 006.
52. Hinojosa, A. E.; Garcia-Bueno, B.; Leza, J. C.; Madrigal, J. L. CCL2/MCP-1 modulation of microglial activation and proliferation. J. Neuroinflammation., 2011, 8, 77. doi: 10. 1186/1742-2094-8-77.
53. Madrigal, J. L.; Garcia-Bueno, B.; Hinojosa, A. E.; Polak, P.; Feinstein, D. L.; Leza J. C. Regulation of MCP-1 production in brain by stress and noradrenaline-modulating drugs. J. Neurochem., 2010, 113, 543-551. DOI: 10. 1111/j. 1471-4159. 2010. 06623. x.
54. Bruno V.; Copani A.; Besong G.; Scoto G.; Nicoletti F. Neuroprotective activity of chemokines against N-methyl-D-aspartate or beta-amyloid-induced toxicity in culture. Eur. J. Pharmacol., 2000, 399, 117-121. DOI: 10. 1016/S0014-2999(00) 00367-8.
55. Bray J. G.; Reyes K. C.; Roberts A. J.; Ransohoff R. M.; Gruol D. L. Synaptic plasticity in the hippocampus shows resistance to acute ethanol exposure in transgenic mice with astrocyte-targeted enhanced CCL2 expression. Neuropharmacology, 2013, 67, 115-125. DOI: 10. 1016/j. neuropharm. 2012. 11. 007.
56. Bose, S. and Cho, J. Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases. Arch. Pharm. Res., 2013, 36, 1039-1050. DOI10. 1007/s12272-013-0161-z.
57. Kiyota, T.; Gendelman, H. E.; Weir, R. A.; Higgins, E. E.; Zhang, G.; Jain, M. CCL2 affects beta-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiol. Aging, 2013, 34, 1060-1068. DOI: 10. 1016/j. neurobiolaging. 2012. 08. 009.
58. Naert, G. and Rivest, S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J. Neurosci., 2011, 31, 6208-6220. DOI: 10. 1016/j. neurobiolaging. 2012. 08. 009.
59. Furukawa, S.; Furukawa, Y.; Satoyoshi, E.; Hayashi, K. Regulation of nerve growth factor synthesis/secretion by catecholamine in cultured mouse astroglial cells. Biochem. Biophys. Res. Commun., 1987, 147, 1048-1054. DOI: 10. 1016/S0006-291X(87)80176-6.
60. Nicole, O.; Ali, C.; Docagne, F.; Plawinski, L.; MacKenzie, E. T.; Vivien, D.; Buisson, A. Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway. J. Neurosci., 2001, 21, 3024-3033. PMID: 11312287.
61. Rudge, J. S.; Alderson, R. F.; Pasnikowski, E.; McClain, J.; Ip, N. Y.; Lindsay, R. M. Expression of Ciliary Neurotrophic Factor and the Neurotrophins-Nerve Growth Factor, Brain-Derived Neuro-trophic Factor and Neurotrophin 3-in Cultured Rat Hippocampal Astrocytes. Eur. J. Neurosci., 1992, 4, 459-471. DOI: 10. 1111/j. 1460-9568. 1992. tb00896. x.
62. Remy, S.; Naveilhan, P.; Brachet, P.; Neveu, I. Differential regulation of GDNF, neurturin, and their receptors in primary cultures of rat glial cells. J. Neurosci. Res., 2001, 64, 242-251. DOI: 10. 1002/jnr. 1072.
63. Condorelli, D. F.; Salin, T.; Dell', A. P.; Mudo, G.; Corsaro, M.; Timmusk, T.; Metsis, M.; Belluardo, N. Neurotrophins and their trk receptors in cultured cells of the glial lineage and in white matter of the central nervous system. J. Mol. Neurosci., 1995, 6, 237-248. DOI10. 1007/BF02736783.
64. Seki, M.; Tanaka, T.; Sakai, Y.; Fukuchi, T.; Abe, H.; Nawa, H.; Takei N. Muller Cells as a source of brain-derived neurotrophic factor in the retina: noradrenaline upregulates brain-derived neurotrophic factor levels in cultured rat Muller cells. Neurochem. Res., 2005, 30, 1163-1170. DOI10. 1007/s11064-005-7936-7.
65. Koyama, Y.; Egawa, H.; Osakada, M.; Baba, A.; Matsuda, T. Increase by FK960, a novel cognitive enhancer, in glial cell line-derived neurotrophic factor production in cultured rat astrocytes. Biochem. Pharmacol., 2004, 68, 275-282. DOI: 10. 1016/j. bcp. 2004. 03. 023.
66. Kajitani, N.; Hisaoka-Nakashima, K.; Morioka, N.; Okada-Tsuchioka, M.; Kaneko, M.; Kasai, M.; Shibasaki, C.; Nakata, Y.; Takebayashi, M. Antidepressant acts on astrocytes leading to an increase in the expression of neurotrophic/growth factors: differential regulation of FGF-2 by noradrenaline. PLoS. One., 2012, 7, e51197. doi: 10. 1371/journal. pone. 0051197.
67. Yan, M.; Dai, H.; Ding, T.; Dai, A.; Zhang, F.; Yu, L.; Chen, G.; Chen, Z. Effects of dexmedetomidine on the release of glial cell line-derived neurotrophic factor from rat astrocyte cells. Neurochem. Int., 2011, 58, 549-557. DOI: 10. 1016/j. neuint. 2011. 01. 013.
68. Nakagawa, T. and Schwartz, J. P. Gene expression profiles of reactive astrocytes in dopamine-depleted striatum. Brain Pathol., 2004, 14, 275-280. DOI: 10. 1111/j. 1750-3639. 2004. tb00064. x.
69. Juric, D. M.; Miklic, S.; Carman-Krzan, M. Monoaminergic neuronal activity up-regulates BDNF synthesis in cultured neonatal rat astrocytes. Brain Res., 2006, 1108, 54-62. DOI: 10. 1016/j. brainres. 2006. 06. 008.
70. Mele, T.; Carman-Krzan, M.; Juric, D. M. Regulatory role of monoamine neurotransmitters in astrocytic NT-3 synthesis. Int. J. Dev. Neurosci., 2010, 28, 13-19. DOI: 10. 1016/j. ijdevneu. 2009. 10. 003.
71. Tomlinson, B. E.; Irving D.; Blessed G. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J. Neurol. Sci., 1981, 49, 419-428. DOI: 10. 1016/0022-510X(81)90031-9.
72. Bondareff, W.; Mountjoy, C. Q.; Roth, M.; Rossor, M. N.; Iversen, L. L.; Reynolds, G. P.; Hauser, D. L. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis. Assoc. Disord., 1987, 1, 256-262. PMID: 3453748.
73. Adolfsson, R.; Gottfries, C. G.; Roos, B. E.; Winblad, B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br. J. Psychiatry, 1979, 135, 216-223. doi: 10. 1192/bjp. 135. 3. 216.
74. Mann, D. M.; Lincoln, J.; Yates, P. O.; Stamp, J. E.; Toper, S. Changes in the monoamine containing neurones of the human CNS in senile dementia. Br. J. Psychiatry, 1980, 136, 533-541. doi: 10. 1192/bjp. 136. 6. 533.
75. Grudzien, A.; Shaw, P.; Weintraub, S.; Bigio, E.; Mash, D. C.; Mesulam, M. M. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol. Aging, 2006, 28, 327-35. DOI: 10. 1016/j. neurobiolaging. 2006. 02. 007.
76. Grudzien, A.; Shaw, P.; Weintraub, S.; Bigio, E.; Mash, D. C.; Mesulam, M. M. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol. Aging, 2007, 28, 327-335. DOI: 10. 1016/j. neurobiolaging. 2006. 02. 007.
77. Zarow, C.; Lyness, S. A.; Mortimer, J. A.; Chui, H. C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol., 2003, 60, 337-341. doi: 10. 1001/archneur. 60. 3. 337.
78. Hertz L. Is Alzheimer's disease an anterograde degeneration, originating in the brainstem, and disrupting metabolic and functional interactions between neurons and glial cells? Brain Res. Brain Res. Rev., 1989, 14, 335-353. DOI: 10. 1016/0165-0173(89)90017-9.
79. Heneka, M. T.; Galea, E.; Gavriluyk, V.; Dumitrescu-Ozimek, L.; Daeschner, J.; O'Banion, M. K.; Weinberg, G.; Klockgether, T.; Feinstein D. L. Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci., 2002, 22, 2434-2442. http://dx. doi. org/ 10. 3410/f. 1005500. 65458.
80. Fritschy, J. M. and Grzanna, R. Selective effects of DSP-4 on locus coeruleus axons: are there pharmacologically different types of noradrenergic axons in the central nervous system? Prog. Brain Res., 1991, 88, 257-268. DOI: 10. 1016/S0079-6123(08)63815-7.
81. Vodovotz, Y.; Lucia, M. S.; Flanders, K. C.; Chesler, L.; Xie, Q. W.; Smith, T. W.; Weidner, J.; Mumford, R.; Webber, R.; Nathan C.; Roberts, A. B.; Lippa, C. F.; Sporn, M. B. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med., 1996, 184, 1425-1433. doi: 10. 1084/jem. 184. 4. 1425.
82. Kalinin S.; Gavrilyuk V.; Polak P. E.; Heneka M. T.; Feinstein D. L. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging, 2006. DOI: 10. 1016/j. neurobiolaging. 2006. 06. 003.
83. Pugh, P. L.; Vidgeon-Hart, M. P.; Ashmeade, T.; Culbert, A. A.; Seymour, Z.; Perren M. J.; Joyce, F.; Bate, S. T.; Babin, A.; Virley D. J.; Richardson, J. C.; Upton, N.; Sunter, D. Repeated administration of the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) modulates neuroinflammation and amyloid plaque load in mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. J. Neuroinflammation., 2007, 4, 8. PMID: 17324270.
84. Heneka, M. T.; Ramanathan, M.; Jacobs, A. H.; Dumitrescu-Ozimek, L.; Bilkei-Gorzo, A.; Debeir, T.; Sastre, M.; Galldiks, N.; Zimmer, A.; Hoehn, M.; Heiss, W. D.; Klockgether, T.; Staufenbiel, M. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci., 2006, 26, 1343-1354. doi: 10. 1523/JNEUROSCI. 4236-05. 2006.
85. Heneka, M. T.; Nadrigny, F.; Regen, T.; Martinez-Hernandez, A.; Dumitrescu-Ozimek, L.; Terwel, D.; Jardanhazi-Kurutz, D.; Walter, J.; Kirchhoff, F.; Hanisch, U. K.; Kummer M. P. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. U. S. A, 2010, 107, 6058-6063. doi: 10. 1073/pnas. 0909586107.
86. Kalinin, S.; Gavrilyuk, V.; Polak, P. E.; Vasser, R.; Zhao, J.; Heneka M. T.; Feinstein, D. L. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging, 2007, 28, 1206-1214. DOI: 10. 1016/j. neurobiolaging. 2006. 06. 003.
87. Jardanhazi-Kurutz, D.; Kummer, M. P.; Terwel, D.; Vogel, K.; Dyrks T.; Thiele, A.; Heneka, M. T. Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem. Int., 2010. DOI: 10. 1016/j. neuint. 2010. 02. 001.
88. O'Neil J. N.; Mouton P. R.; Tizabi Y.; Ottinger M. A.; Lei D. L.; Ingram D. K.; Manaye K. F. Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J. Chem. Neuroanat., 2007, 34, 102-107. DOI: 10. 1016/j. jchemneu. 2007. 05. 008.
89. Guerin, D.; Sacquet, J.; Mandairon N.; Jourdan F.; Didier A. Early locus coeruleus degeneration and olfactory dysfunctions in Tg2576 mice. Neurobiol. Aging, 2007. DOI: 10. 1016/j. neurobiolaging. 2007. 05. 020.
90. Li L.; Cheung T.; Chen J.; Herrup K. A comparative study of five mouse models of Alzheimer's disease: cell cycle events reveal new insights into neurons at risk for death. Int. J. Alzheimers. Dis., 2011, 2011, 171464. http://dx. doi. org/10. 4061/2011/171464.
91. Braak, H. and Del, T. K. Where, when, and in what form does sporadic Alzheimer's disease begin? Curr. Opin. Neurol., 2012, 25, 708-714. doi: 10. 1097/WCO. 0b013e32835a3432.
92. Attems, J.; Thal, D. R.; Jellinger, K. A. The relationship between subcortical tau pathology and Alzheimer's disease. Biochem. Soc. Trans., 2012, 40, 711-715. doi: 10. 1042/BST20120034.
93. Arenas, E. and Persson, H. Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo. Nature, 1994, 367, 368-371. doi: 10. 1038/367368a0.
94. Holm, P. C.; Rodriguez, F. J.; Kresse, A.; Canals, J. M.; Silos-Santiago I.; Arenas, E. Crucial role of TrkB ligands in the survival and phenotypic differentiation of developing locus coeruleus noradrenergic neurons. Development, 2003, 130, 3535-3545. doi: 10. 1242/dev. 00565.
95. Counts, S. E. and Mufson, E. J. Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J. Neurochem., 2010. DOI: 10. 1111/j. 1471-4159. 2010. 06622. x.
96. Luellen, B. A.; Bianco, L. E.; Schneider, L. M.; Andrews, A. M. Reduced brain-derived neurotrophic factor is associated with a loss of serotonergic innervation in the hippocampus of aging mice. Genes Brain Behav., 2007, 6, 482-490. DOI: 10. 1111/j. 1601-183X. 2006. 00279. x.
97. Matsunaga, W.; Shirokawa, T.; Isobe, K. BDNF is necessary for maintenance of noradrenergic innervations in the aged rat brain. Neurobiol Aging, 2004, 25, 341-348. DOI: 10. 1016/S0197-4580(03)00093-9.
98. Nakai S.; Matsunaga W.; Ishida Y.; Isobe K.; Shirokawa T. Effects of BDNF infusion on the axon terminals of locus coeruleus neurons of aging rats. Neurosci. Res., 2006, 54, 213-219. DOI: 10. 1016/j. neures. 2005. 12. 001.
99. Friedman, W. J.; Black, I. B.; Kaplan, D. R. Distribution of the neurotrophins brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 in the postnatal rat brain: an immuno-cytochemical study. Neuroscience, 1998, 84, 101-114. DOI: 10. 1016/S0306-4522(97)00526-5.
100. Rajda, C.; Bencsik, K.; Fuvesi, J.; Seres, E.; Vecsei, L.; Bergquist, J. The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients. Mult. Scler., 2006, 12, 265-270. doi: 10. 1191/135248506ms1269oa.
101. Cosentino M.; Zaffaroni M.; Marino F.; Bombelli R.; Ferrari M.; Rasini E.; Lecchini S.; Ghezzi A.; Frigo G. Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J. Neuroimmunol., 2002, 133, 233-240. DOI: 10. 1016/S0165-5728(02)00372-7.
102. Zoukos, Y.; Leonard, J. P.; Thomaides, T.; Thompson, A. J.; Cuzner, M. L. beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. Ann. Neurol., 1992, 31, 657-662. PMID: 1325138.
103. Chelmicka-Schorr, E.; Checinski, M.; Arnason, B. G. Chemical sympathectomy augments the severity of experimental allergic encephalomyelitis. J. Neuroimmunol., 1988, 17, 347-350. DOI: 10. 1016/0165-5728(88)90125-7.
104. Leonard, J. P.; MacKenzie, F. J.; Patel, H. A.; Cuzner, M. L. Hypothalamic noradrenergic pathways exert an influence on neuroendocrine and clinical status in experimental autoimmune encephalomyelitis. Brain Behav. Immun., 1991, 5, 328-338. DOI: 10. 1016/0889-1591(91)90028-9.
105. Chelmicka-Schorr, E.; Wollmann, R. L.; Kwasniewski, M. N.; Kim, D. H.; Dupont, B. L. The beta 2-adrenergic agonist terbutaline suppresses acute passive transfer experimental autoimmune myasthenia gravis (EAMG). Int. J. Immunopharmacol., 1993, 15, 19-24. DOI: 10. 1016/0192-0561(93)90027-V.
106. Wiegmann, K.; Muthyala, S.; Kim, D. H.; Arnason, B. G.; Chelmicka-Schorr E. Beta-adrenergic agonists suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis rats. J. Neuroimmunol., 1995, 56, 201-206. DOI: 10. 1016/0165-5728(94)00153-F.
107. Khoruzhaia, T. A. and Saakov, B. A. [Change in monoamine content and monoamine oxidase activity in brain structures during experimental allergic encephalomyelitis]. Biull. Eksp. Biol. Med., 1975, 79, 80-82. PMID: 1222257.
108. Krenger W.; Honegger C. G.; Feurer C.; Cammisuli S. Changes of neurotransmitter systems in chronic relapsing experimental allergic encephalomyelitis in rat brain and spinal cord. J. Neurochem., 1986, 47, 1247-1254. DOI: 10. 1111/j. 1471-4159. 1986. tb00747. x.
109. White, S. R.; Bhatnagar, R. K.; Bardo, M. T. Norepinephrine depletion in the spinal cord gray matter of rats with experimental allergic encephalomyelitis. J. Neurochem., 1983, 40, 1771-1773. DOI: 10. 1111/j. 1471-4159. 1983. tb08156. x.
110. Barkhatova, V. P.; Zavalishin, I. A.; Askarova, L. S.; Shavratskii, V. K.; Demina, E. G. Changes in neurotransmitters in multiple sclerosis. Neurosci. Behav. Physiol, 1998, 28, 341-344. DOI10. 1007/BF02464784.
111. Zeinstra, E.; Wilczak, N.; De Keyser, J. [3H]dihydroalprenolol binding to beta adrenergic receptors in multiple sclerosis brain. Neurosci. Lett., 2000, 289, 75-77. DOI: 10. 1016/S0304-3940(00) 01254-4.
112. Polak P. E.; Kalinin S.; Feinstein D. L. Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain, 2011, 134, 665-677. doi: 10. 1093/brain/awq362.
113. Jovanova-Nesic, K.; Nikolic, V.; Jankovic, B. D. Locus ceruleus and immunity. II. Suppression of experimental allergic encephalomyelitis and hypersensitivity skin reactions in rats with lesioned locus ceruleus. Int. J. Neurosci., 1993, 68, 289-294. DOI: 10. 3109/00207459308994284.
114. Vollmar P.; Nessler S.; Kalluri S. R.; Hartung H. P.; Hemmer B. The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int. J. Neuropsychopharmacol., 2008, 1-12. http://dx. doi. org/10. 1017/S1461145708009425.
115. Paintlia A. S.; Paintlia M. K.; Singh I.; Skoff R. B.; Singh A. K. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia, 2008, 57, 182-93. DOI: 10. 1002/glia. 20745.
116. Labatut, R.; Richard, F.; Milne, B.; Quintin, L.; Lecestre, D.; Pujol, J. F. Long-term effects of RU24722 on tyrosine hydroxylase of the rat brain. J. Neurochem., 1988, 51, 1367-1374. DOI: 10. 1111/j. 1471-4159. 1988. tb01099. x.
117. Zyzek, E.; Richard, F.; Bouilloux, J. P.; Pujol, J. F. Ontogeny of tyrosine hydroxylase concentration in locus coeruleus of newborn rats: long-term effects of RU24722. J. Neurochem., 1990, 55, 849-853. DOI: 10. 1111/j. 1471-4159. 1990. tb04569. x.
118. Ginovart, N.; Marcel, D.; Bezin, L.; Gagne, C.; Pujol, J. F.; Weissmann D. Tyrosine hydroxylase expression within Balb/C and C57black/6 mouse locus coeruleus. II. Quantitative study of the enzyme level. Brain Res., 1996, 719, 45-55. DOI: 10. 1016/0006-8993(96)00075-3.
119. Bezin, L.; Marcel, D.; Desgeorges, S.; Pujol, J. F.; Weissmann, D. Singular subsets of locus coeruleus neurons may recover tyrosine hydroxylase phenotype transiently expressed during development. Brain Res. Mol. Brain Res., 2000, 76, 275-281. DOI: 10. 1016/S0169-328X(00)00007-3.
120. Polak, P. E.; Kalinin, S.; Braun, D.; Sharp, A.; Lin S. X.; Feinstein, D. L. The vincamine derivative vindeburnol provides benefit in a mouse model of multiple sclerosis: effects on the Locus coeruleus. J. Neurochem., 2012, 121, 206-216. DOI: 10. 1111/j. 1471-4159. 2012. 07673. x.
121. Vanderheyden, W. M.; Poe, G. R.; Liberzon, I. Trauma exposure and sleep: using a rodent model to understand sleep function in PTSD. Exp. Brain Res., 2014, 232, 1575-1584. DOI: 10. 1007/s00221-014-3890-4.
122. Pietrzak, R. H.; Gallezot, J. D.; Ding, Y. S.; Henry, S.; Potenza, M. N.; Southwick, S. M.; Krystal, J. H.; Carson, R. E.; Neumeister, A. Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry, 2013, 70, 1199-1205. doi: 10. 1001/jamapsychiatry. 2013. 399.
123. Salehi, A.; Faizi, M.; Colas, D.; Valletta, J.; Laguna, J.; Takimoto-Kimura, R.; Kleschevnikov, A.; Wagner, S. L.; Aisen, P.; Shamloo M.; Mobley, W. C. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci. Transl. Med., 2009, 1, 7ra17. DOI: 10. 1126/scitranslmed. 3000258.
124. Oakley, H.; Cole, S. L.; Logan, S.; Maus, E.; Shao, P.; Craft, J.; Guillozet-Bongaarts, A.; Ohno, M.; Disterhoft, J.; Van, E. L.; Berry, R.; Vassar, R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci., 2006, 26, 10129-10140. doi: 10. 1523/JNEUROSCI. 1202-06. 2006.